Abstract Objective To study the association between two single nucleotide polymorphisms (SNP), rs2295080 and rs2536, in mammalian target of rapamycin (mTOR) gene and the susceptibility to pediatric epilepsy. Methods A case-control study was performed on 480 children with epilepsy (116 cases of refractory epilepsy) and 503 healthy children. SNP rs2295080 and rs2536 in the mTOR gene were detected by polymerase chain reaction restriction and fragment length polymorphisms (PCR-RFLP). Genotype and allele frequencies of SNP rs2295080 and rs2536 were compared between the children with epilepsy and healthy controls. Results There were no significant differences in the genotype and allele frequencies of SNP rs2295080 between the children with epilepsy and healthy controls. There were no significant differences in the genotype frequencies of SNP rs2536 between the two groups either, but the frequency of G allele of SNP rs2536 was higher in children with epilepsy than that in healthy controls (P=0.042, OR=1.344, 95%CI:1.010-1.789). Conclusions SNP rs2536 of mTOR gene may be associated with the risk of pediatric epilepsy.
About author:: 10.7499/j.issn.1008-8830.2015.06.005
Cite this article:
YUE Xin,ZHAO Pei-Wei,LIU Zhi-Sheng et al. Association of mammalian target of rapamycin gene polymorphisms with the risk of pediatric epilepsy[J]. CJCP, 2015, 17(6): 560-564.
YUE Xin,ZHAO Pei-Wei,LIU Zhi-Sheng et al. Association of mammalian target of rapamycin gene polymorphisms with the risk of pediatric epilepsy[J]. CJCP, 2015, 17(6): 560-564.
Lipton JO, Sahin M. The neurology of mTOR [J]. Neuron, 2014, 84(2):275-291.
[2]
Zeng LH, Rensing NR, Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy [J]. J Neurosci, 2009, 29(21):6964-6972.
[3]
Shao JB, Li Y, Zhao PW, et al. Association of mTOR polymorphisms with cancer risk and clinical outcomes:a metaanalysis[J]. PloS one, 2014, 9(5):e97085.
[4]
Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy:definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) [J]. Epilepsia, 2005, 46(4):470-472.
[5]
Kwiatkowski DJ. Tuberous sclerosis:from tubers to mTOR [J]. Ann Hum Genet, 2003, 67(Pt1):87-96.
[6]
Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSCmTOR pathway in human disease [J]. Nat Genet, 2005, 37(1):19-24.
Galanopoulou AS, Gorter JA, Cepeda C. Finding a better drug for epilepsy:The mTOR pathway as an antiepileptogenic target[J]. Epilepsia, 2012, 53(7):1119-1130.
[9]
Lee JH, Huynh M, Silhavy JL, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly [J]. Nat Genet, 2012, 44(8):941-945.
[10]
Poduri A, Evrony GD, Cai X, et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations [J]. Neuron, 2012, 74(1):41-48.
[11]
Epi4K Consortium; Epilepsy Phenome/Genome Project (Allen AS, Berkovic SF, Cossette P, et al). De novo mutations in epileptic encephalopathies [J]. Nature, 2013, 501(7466):217- 221.
Cao Q, Ju X, Li P, et al. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk [J]. PLoS One, 2012, 7(11):e50302.
[14]
Li Q, Gu C, Zhu Y, et al. Polymorphisms in the mTOR gene and risk of sporadic prostate cancer in an Eastern Chinese population[J]. PLoS One, 2013, 8(8):e71968.
[15]
Huang L, Huang J, Wu P, et al. Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population [J]. Leuk Lymphoma, 2012, 53(5):947- 951.
